Royal Bank Of Canada Lowers argenex (NASDAQ:ARGX) Price Target to $890.00

argenex (NASDAQ:ARGX) had its price target reduced by research analysts at Royal Bank Of Canada from $925.00 to $890.00 in a research report issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective suggests a potential upside of 16.05% from the company’s current price.

A number of other research firms also recently issued reports on ARGX. TD Cowen upped their price target on shares of argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Wolfe Research restated a “peer perform” rating on shares of argenex in a report on Monday, November 24th. Stifel Nicolaus upped their target price on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price target on argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Finally, Piper Sandler boosted their price objective on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and an average target price of $999.22.

argenex Stock Performance

NASDAQ:ARGX opened at $766.92 on Friday. The stock has a 50-day simple moving average of $826.36 and a two-hundred day simple moving average of $811.97. The firm has a market capitalization of $47.46 billion, a PE ratio of 39.29, a P/E/G ratio of 0.67 and a beta of 0.37. argenex has a 52-week low of $510.05 and a 52-week high of $934.62.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.05 by $1.97. The firm had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a return on equity of 63.59% and a net margin of 30.42%. Equities analysts forecast that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenex

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of argenex during the fourth quarter worth $5,080,000. Dorsey Wright & Associates acquired a new stake in shares of argenex in the 4th quarter worth $1,244,000. Compound Planning Inc. grew its stake in argenex by 120.7% during the 4th quarter. Compound Planning Inc. now owns 1,302 shares of the company’s stock worth $1,095,000 after buying an additional 712 shares during the last quarter. Invesco Ltd. increased its position in argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after buying an additional 331,489 shares in the last quarter. Finally, Corient Private Wealth LLC increased its position in argenex by 12,441.8% during the 4th quarter. Corient Private Wealth LLC now owns 246,572 shares of the company’s stock valued at $207,355,000 after buying an additional 244,606 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.